IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

PAR PHARMACEUTICAL, INC.,
Petitioner,

v.

HORIZON THERAPEUTICS, INC.,
Patent Owner.

Case IPR2017-01767
Patent 9,254,278

PETITIONER PAR PHARMACEUTICAL, INC.'S UPDATED EXHIBIT LIST

Mail Stop "PATENT BOARD"
Patent Trial and Appeal Board
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

List of Exhibits and Abbreviations for Exhibits

EXHIBIT NO.	DESCRIPTION	ABBREVIATION (if applicable)
1001	U.S. Patent No. 9,254,278 to Scharschmidt et al., filed August 3, 2015, issued February 9, 2016	the '278 Patent
1002	Declaration of Dr. Neal Sondheimer	
1003	*Curriculum vitae* of Dr. Neal Sondheimer	
1004	U.S. Patent Publication No. 2010/0008859, filed January 7, 2009, published January 14, 2010	the '859 Publication
1005	Moser et al., *Argininoscuccinic Aciduria Report of Two New Cases and Demonstration of Intermittent Elevation of Blood Ammonia*, 42 Am. J. Medicine, 9-26 (1967)	Moser
1006	*Blau*, *Duran*, *Blaskovics*, *Gibson* (editors), *Physician's Guide to the Laboratory Diagnosis of Metabolic Diseases*, 261–276 (2d ed. 1996)	Blau
1007	Simell et al., *Waste Nitrogen Excretion Via Amino Acid Acylation: Benzoate and Phenylacetate in Lysinuric Protein Intolerance*, 20 Pediatric Research, 1117–1121 (1986)	Simell
1008	Feillet et al., *Alternative Pathway Therapy for Urea Cycle Disorders*, 21 Journal of Inherited Metabolic Disease Suppl 1, 101-111 (1998)	Feillet

EXHIBIT NO.	DESCRIPTION	ABBREVIATION (if applicable)
1009	Scientific Discussion for Ammonaps, EMEA, 1-12 (2005)	Ammonaps
1010	Lee et al., *Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: Safety, pharmacokinetics and ammonia control*, 100 Molecular Genetics and Metabolism, 221-228 (2010)	Lee
1011	Buphenyl Label	
1012	Prosecution History of U.S. Patent No. 8,404,215	the '215 Parent Patent
1013	Assignment History of U.S. Patent 8,642,012	
1014	'278 Patent Infringement Complaint with Return of Service	
1015	Fernandes et al., *Inborn Metabolic Diseases Diagnosis and Treatment*, 214-22 (J. Fernandes et al., eds., 3d ed. 2002)	Fernandes
1016	Leonard et al., *Hypothesis: Proposals for the Management of a Neonate at Risk of Hyperammonaemia Due to a Urea Cycle Disorder*, 167 Eur. J. Pediatr. 305-309 (2008)	Leonard 2008
1017	Lichter-Konecki et al., *Ammonia Control in Children with Urea Cycle Disorders (UCDs): Phase 2 Comparison of Sodium Phenylbutyrate and Glycerol Phenylbutyrate*, 103 Molecular Genetics and Metabolism, 323-329 (2011)	Lichter-Konecki

EXHIBIT NO.	DESCRIPTION	ABBREVIATION (if applicable)
1018	Pandya et al., *N-Acetylglutamate Synthetase Deficiency: Clinical and Laboratory Observations*, 14 J. Inher. Metab. Dis. 685-690 (1991)	Pandya
1019	U.S. Patent No. 5,968,979	the '979 patent
1020	McGuire et al., *Pharmacology and Safety of Glycerol Phenylbutyrate in Healthy Adults and Adults with Cirrhosis*, 51(6) Hepatology 2077-2085 (2010)	McGuire
1021	Diaz et al., *Phase 3 Blinded, Randomized, Crossover Comparison of Sodium Phenylbutyrate (NaPBA) and glycerol phenylbutyrate (GPB): Ammonia (NH3) Control in Adults with Urea Cycle Disorders (UCDs)*, 102 Molecular Genetics and Metabolism 276-77 (2011)	Diaz
1022	Barsotti, *Measurement of Ammonia in Blood*, 138 J. Pediatrics, S11-S20 (2001)	Barsotti
1023	Yajima, et al., *Diurnal Fluctuations of Blood Ammonia Levels in Adult-Type Citrullinemia*, 137 Tokohu J. Ex/ Med, 213-220 (1982)	Yajima
1024	Batshaw, et al., *Treatment of Carbamyl Phosphate Synthetase Deficiency with Keto Analogues of Essential Amino Acids*, 292 New Eng. J. Med. 1085−90 (1975)	Batshaw

EXHIBIT NO.	DESCRIPTION	ABBREVIATION (if applicable)
1025	Brusilow, *Phenylacetylglutamine May Replace Urea as a Vehicle for Waste Nitrogen Excretion*, 29 Pediatric Research, 147-150 (1991)	Brusilow '91
1026	Enns Deposition Ex. 1026, Fernandes et al., *Inborn Metabolic Diseases Diagnosis and Treatment*, 214-22 (J. Fernandes et al., eds., 3d ed. 2002)	
1027	Transcript of July 18, 2018 Deposition of Dr. Gregory M. Enns	
1028	Reply Declaration of Dr. Neal Sondheimer	

Dated: August 16, 2018



David H. Silverstein (Reg. No. 61,948)
AXINN, VELTROP & HARKRIDER LLP
114 West 47th Street, 22nd Floor
New York, NY 10036
(212) 261-5651

Counsel for Petitioner
Par Pharmaceutical, Inc.

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.